Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR1F | P30939 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095944 | 0.84 | HTR1F (0.53) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL30909151 | 0.84 | HTR1F (0.53) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL7010491 | 0.79 | HTR1F (0.49) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL3627711 | 0.77 | SLC6A4 (0.64) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL7010139 | 0.76 | HTR1F (0.65) | HTR1AHTR6HTR1F | |
| SCHEMBL7012929 | 0.75 | HTR1F (0.51) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL7012793 | 0.74 | HTR1F (0.76) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL7011713 | 0.74 | SLC6A4 (0.60) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL30909106 | 0.73 | HTR1F (0.48) | SLC6A4KDM4ELMNAPOLBHTR1A | |
| SCHEMBL7005055 | 0.73 | HTR1F (0.48) | SLC6A4KDM4ELMNAPOLBHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| EP-0916670-B1 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-0916670-A2 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | SLC6A4 299/4885KDM4E 3551/4885LMNA 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.